EMPEGFILGRASTIM
Myelosuppression
Moscow Clinical Scientific Centerprotein_peptideDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Myelosuppression cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Docetaxel The First Affiliated Hospital of Xiamen University | Phase 2 | B |
Trilaciclib The First Affiliated Hospital of Xiamen University | Phase 2 | B |
Myelo001 Myelo Therapeutics GmbH | Phase 2 | B |
Sacituzumab Tirumotecan The First Affiliated Hospital of Xiamen University | Phase 2 | CCC |
SULANEMADLIN Aileron Therapeutics, Inc. | Phase 1 | CC |
Same molecule, other indications
EMPEGFILGRASTIM is also rated in:
Patients With Solid Tumours Who Receive Myelosupressive TherapyDormant
D
Indicative ·
30 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →